LGND Quote, Financials, Valuation and Earnings

Dare Bioscience has a net margin of -72.62% compared to Ligand Pharmaceuticals's net margin of -11279.42%. Ligand Pharmaceuticals's return on equity of -0.51% beat Dare Bioscience's return on equity of --.

Ligand Pharmaceuticals has a consensus price target of $143.50, signalling upside risk potential of 35.7%. On the other hand Dare Bioscience has an analysts' consensus of $13.33 which suggests that it could grow by 344.44%. Given that Dare Bioscience has higher upside potential than Ligand Pharmaceuticals, analysts believe Dare Bioscience is more attractive than Ligand Pharmaceuticals.

Ligand Pharmaceuticals has a beta of 1.099, which suggesting that the stock is 9.858% more volatile than S&P 500. In comparison Dare Bioscience has a beta of 1.342, suggesting its more volatile than the S&P 500 by 34.208%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dare Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. Dare Bioscience pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals quarterly revenues are $42.8M, which are larger than Dare Bioscience quarterly revenues of $41.7K. Ligand Pharmaceuticals's net income of -$31.1M is lower than Dare Bioscience's net income of -$4.7M. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 46.13x while Dare Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 11.63x versus 2,561.03x for Dare Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -72.62% compared to Ligand Pharmaceuticals's net margin of 50.24%. Ligand Pharmaceuticals's return on equity of -0.51% beat Johnson & Johnson's return on equity of 30.18%.

Ligand Pharmaceuticals has a consensus price target of $143.50, signalling upside risk potential of 35.7%. On the other hand Johnson & Johnson has an analysts' consensus of $169.84 which suggests that it could grow by 9.31%. Given that Ligand Pharmaceuticals has higher upside potential than Johnson & Johnson, analysts believe Ligand Pharmaceuticals is more attractive than Johnson & Johnson.

Ligand Pharmaceuticals has a beta of 1.099, which suggesting that the stock is 9.858% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.19% to investors and pays a quarterly dividend of $1.24 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ligand Pharmaceuticals quarterly revenues are $42.8M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Ligand Pharmaceuticals's net income of -$31.1M is lower than Johnson & Johnson's net income of $11B. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 46.13x while Johnson & Johnson's PE ratio is 17.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 11.63x versus 4.22x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -72.62% compared to Ligand Pharmaceuticals's net margin of 32.59%. Ligand Pharmaceuticals's return on equity of -0.51% beat Eli Lilly and's return on equity of 80.24%.

Ligand Pharmaceuticals has a consensus price target of $143.50, signalling upside risk potential of 35.7%. On the other hand Eli Lilly and has an analysts' consensus of $1,008.64 which suggests that it could grow by 21.61%. Given that Ligand Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Ligand Pharmaceuticals is more attractive than Eli Lilly and.

Ligand Pharmaceuticals has a beta of 1.099, which suggesting that the stock is 9.858% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.50 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ligand Pharmaceuticals quarterly revenues are $42.8M, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Ligand Pharmaceuticals's net income of -$31.1M is lower than Eli Lilly and's net income of $4.4B. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 46.13x while Eli Lilly and's PE ratio is 70.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 11.63x versus 16.65x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -72.62% compared to Ligand Pharmaceuticals's net margin of -49.65%. Ligand Pharmaceuticals's return on equity of -0.51% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Ligand Pharmaceuticals has a consensus price target of $143.50, signalling upside risk potential of 35.7%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 47.26%. Given that NovaBay Pharmaceuticals has higher upside potential than Ligand Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Ligand Pharmaceuticals.

Ligand Pharmaceuticals has a beta of 1.099, which suggesting that the stock is 9.858% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals quarterly revenues are $42.8M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Ligand Pharmaceuticals's net income of -$31.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 46.13x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 11.63x versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.